MAX Chat
Share chart Dyne Therapeutics, Inc.
Extended chart
Simple chart
Main settings
Currency
usd
IPO Time
2020-09-17
ISIN
US26818M1080
Industry
Biotechnology
Report Currency
usd
Sector
Health Care
Website
Grade
Underestimation
| Title | Value | Grade |
| P/S | 0 | 0 |
| P/BV | 3.52 | 5 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -74.14 | 0 |
| ROE | -88.03 | 0 |
| ROIC | -36.69 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -0.0761 | 10 |
| Debt/Ratio | 0.0347 | 10 |
| Debt/Equity | 0.0975 | 10 |
Growth impulse
| Title | Value | Grade |
| Revenue, bln, % | 16766.67 | 10 |
| Ebitda, % | 437.84 | 10 |
| EPS, % | -18.36 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 14.46 $ | 0 $ | 0 $ | -0.1383 % | 0 % | 0 % |
| Week | 14.7 $ | 0 $ | 0 $ | -1.77 % | 0 % | 0 % |
| Month | 11.9 $ | 0 $ | 0 $ | +21.34 % | 0 % | 0 % |
| Three month | 7.55 $ | 11.66 $ | 14.78 $ | +91.26 % | 0 % | 0 % |
| Half a year | 14.79 $ | 6.81 $ | 14.78 $ | -2.37 % | 0 % | 0 % |
| Year | 44.03 $ | 6.81 $ | 47.04 $ | -67.2 % | 0 % | 0 % |
| 3 years | 11.67 $ | 6.62 $ | 47.04 $ | +23.74 % | 0 % | 0 % |
| 5 years | 4.36 $ | 4.36 $ | 47.04 $ | +331.19 % | 0 % | 0 % |
| 10 years | 4.36 $ | 4.36 $ | 47.04 $ | +331.19 % | 0 % | 0 % |
| Year to date | 24.76 $ | 6.81 $ | 25.46 $ | -41.68 % | 0 % | 0 % |
Main owners
Contained in ETF
ETF | Share, % | Profitability for 1 year, % | Commission, % |
| Future Tech ETF | 0.35641 | 479.5 | 0.35 |
| Principal Healthcare Innovators ETF | 0.35641 | -3.92 | 0.35 |
| iShares Morningstar Small-Cap Value ETF | 0.06269 | 175.97 | 0.06 |
| iShares Morningstar Small-Cap ETF | 0.05548 | 299.3 | 0.25 |
| iShares Morningstar Small-Cap Growth ETF | 0.04907 | 557.86 | 0.06 |
| 0.18 | 301.74 | 0.21 |
|---|
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Dr. Romesh Subramanian Ph.D. | Co-Founder & Advisor | 565.17k | 1965 (60 years) |
| Dr. Oxana Beskrovnaya Ph.D. | Chief Scientific Officer | 631.08k | 1961 (64 years) |
| Ms. Amy Reilly | Senior VP and Head of Corporate Communications & Investor Relations | N/A | 1974 (51 year) |
| Ms. Debra Feldman | Chief Regulatory Affairs Officer | N/A | 1971 (54 years) |
| Mr. Richard William Scalzo M.B.A. | Senior VP and Head of Finance & Administration | N/A | 1986 (39 years) |
| Mr. Daniel Wilson | Senior VP & Head of Legal | N/A | 1972 (53 years) |
| Mr. John Najim M.B.A. | Chief Technical Officer | N/A | |
| Mr. John G. Cox M.B.A. | CEO, President & Director | 1963 (62 years) | |
| Ms. Lucia Celona | Chief Human Resource Officer | 1966 (59 years) | |
| Dr. Ashish Dugar M.B.A., Ph.D. | Chief Medical Affairs Officer |
About company
Address: United States, Waltham, 830 Winter Street - Open in google maps, Open in yandex maps
Website: https://www.dyne-tx.com
Website: https://www.dyne-tx.com
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., компания, занимающаяся заболеваниями мышц, работает как биотехнологическая компания, которая занимается продвижением терапевтических средств для лечения генетически обусловленных заболеваний мышц в Соединенных Штатах. Он разрабатывает различные программы для миотонической дистрофии 1 типа, мышечной дистрофии Дюшенна и фациоскапуло-плечевой дистрофии, а также для лечения редких заболеваний скелетных мышц, сердечных и метаболических мышц, используя платформу FORCE, которая обеспечивает терапию, изменяющую заболевание. Компания была основана в 2017 году, ее штаб-квартира находится в Уолтеме, штат Массачусетс.
